| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | -0.0022 | 0.9 |